Skip to main content
. 2018 Mar 15;6(2):174–179. doi: 10.1016/j.esxm.2017.12.004

Table 1.

Severity and duration of symptoms related to post-orgasmic illness syndrome before and 8 and 15 months after intralymphatic immunotherapy

Symptom Severity (VAS, mm)
Duration (h)
Baseline → 8 mo → 15 mo Baseline → 8 mo → 15 mo
General
 Weakness 100 → 80 → 70 48 → 40 → 40
 Fatigue 100 → 80 → 70 48 → 40 → 40
 Fever 100 → 50 → 20 48 → 24 → 12
 Feverishness 100 → 50 → 20 48 → 24 → 12
 Chill 100 → 50 → 20 48 → 24 → 12
 Malaise 100 → 80 → 60 48 → 48 → 48
 Myalgia 100 → 80 → 60 48 → 48 → 48
 Arthralgia 100 → 80 → 60 48 → 48 → 48
Ocular
 Burning sensation 100 → 60 → 60 48 → 36 → 40
Respiratory
 Rhinorrhea 100 → 60 → 60 48 → 36 → 36
 Sneezing 100 → 60 → 0 48 → 36 → 0
 Sore throat 60 → 60 → 60 48 → 48 → 48
 Sputum 100 → 50 → 40 48 → 24 → 24
Gastrointestinal
 Anorexia 100 → 70 → 70 48 → 40 → 24
Urinary
 Residual urine sensation 80 → 80 → 80 48 → 48 → 48
 Voiding difficulty 80 → 80 → 80 48 → 48 → 48
 Weak stream 80 → 80 → 80 48 → 48 → 48
 Dribbling 80 → 80 → 80 48 → 48 → 48
Neuropsychiatric
 Depression 100 → 80 → 50 48 → 40 → 24
 Anxiety 100 → 50 → 40 48 → 24 → 20
 Irritability 100 → 80 → 80 48 → 40 → 36

VAS = visual analog scale.

The VAS ranged from 0 to 100 mm.